海普瑞FOYA获奖坪山工厂如何用AI、5G与自动化提升无菌预灌封注射器生产
How Hepalink's FOYA-Winning Pingshan Facility Uses Artificial Intelligence (AI), 5G, and Automation to Improve Sterile Manufacturing
海普瑞深圳坪山新建预灌封注射器工厂获2026年ISPE设施年度奖(FOYA)创新—新技术类别奖,整合自动化仓储、隔离器灌装、AI视觉检测、AGV与5G连接,支撑年产3.3亿支无菌预灌封注射器。工厂采用垂直布局以在有限工业用地内扩大产能,并通过坪山与南山两基地的数字互联共享库存、生产计划与质量信息,提升供应可靠性。
How can pharmaceutical manufacturers increase production capacity, strengthen sterility assurance, and improve supply reliability when facility space is limited?
Hepalink's Shenzhen Pingshan New Pre-Filled Syringe Manufacturing Facility offers one answer. Recognized with the 2026 ISPE Facility of the Year Awards (FOYA) Innovation - Novel Technology Category Award, the facility combines advanced automation, 5G connectivity, artificial intelligence (AI), automated guided vehicles (AGVs), and a vertically integrated design to support the production of 330 million sterile prefilled syringes annually.
In a recent episode of ISPE Podcast: Shaping the Future of Pharma, CaiXue Wei, Vice President of Manufacturing and Operations, Global Industrial Affairs at Hepalink, shared how the category award-winning facility was designed to address multiple manufacturing challenges simultaneously, from capacity constraints and sterility assurance to digital coordination and global supply resilience.
The conversation provides valuable insights into how pharmaceutical manufacturers can apply practical innovation to solve real-world production challenges while improving quality, efficiency, and patient outcomes.
What Is the Hepalink Pingshan Facility?
The Shenzhen Hepalink Pingshan New Pre-Filled Syringe Manufacturing Facility is a large-scale sterile manufacturing facility designed to produce high-viscosity prefilled syringes while meeting international quality and sterility standards.
Unlike facilities built around a single breakthrough technology, Pingshan was designed as an integrated manufacturing ecosystem. The facility combines:
- Automated warehousing
- Isolator-based filling technology
- AI-powered visual inspection
- Automated guided vehicles (AGVs)
- 5G-enabled connectivity
- Digital manufacturing systems
Together, these technologies support annual production capacity of 330 million units while improving operational efficiency, quality oversight, and supply stability.
According to Wei, the facility's FOYA recognition reflects its system-level approach to innovation.
Why Did Hepalink Build the Facility Vertically?
One of the most distinctive features of the Pingshan facility is its vertical design.
Hepalink adopted a vertical facility layout to maximize manufacturing capacity in a region where available industrial land is limited.
Located in Shenzhen, a densely populated urban area, the project team needed a way to support large-scale sterile manufacturing without significantly expanding the facility footprint.
By vertically integrating the following, the facility reduces material travel distances, improves space utilization, and supports higher production volumes within a smaller footprint.
- Automated warehouses
- Filling operations
- Packaging lines
- Material-transfer systems
The approach demonstrates how facility design can help solve both operational and geographic constraints.
How Does 5G Improve Pharmaceutical Manufacturing?
At the Pingshan facility, 5G serves as the connectivity layer that links manufacturing operations, quality systems, equipment, and logistics processes.
The facility's localized 5G-MEC infrastructure supports:
- AGV dispatching
- AI image transmission
- Equipment monitoring
- Manufacturing execution systems and supervisory control and data acquisition systems data collection
- Real-time operational visibility
According to Wei, this connectivity enables faster information exchange across production, logistics, and quality systems, improving responsiveness and operational stability.
As more manufacturers pursue digital transformation initiatives, robust connectivity infrastructure is becoming increasingly important for supporting integrated manufacturing operations.
How Are AGVs Improving Efficiency and Quality?
The facility uses automated guided vehicles and conveyor systems throughout key material-transfer processes.
Benefits include:
- Reduced manual material handling
- Improved logistics efficiency
- Faster production coordination
- Reduced operator intervention
- Enhanced quality oversight
- Improved safety performance
Rather than spending time transporting materials, operators can focus on higher-value activities such as process coordination, scheduling verification, handoffs, and exception management.
This shift allows employees to spend less time on repetitive tasks and more time supporting manufacturing performance.
How Is AI Being Used in Pharmaceutical Manufacturing at Pingshan?
AI plays an important role in both product inspection and manufacturing oversight.
AI-Powered Visual Inspection
The facility uses AI and multi-camera imaging systems to identify defects such as:
- Particles
- Air bubbles
- Cracks
- Surface scratches
This improves inspection consistency while increasing the ability to detect critical quality defects.
AI-Supported Shop Floor Management
AI is also used to monitor activities in critical manufacturing areas and identify potential quality risks earlier in the process.
Rather than relying exclusively on post-production inspection, Hepalink is using AI to support a more proactive quality-management approach focused on real-time monitoring and risk prevention.
How Do the Pingshan and Nanshan Facilities Work Together?
Supply reliability was a major focus of the project.
Through digital integration, Hepalink's Pingshan and Nanshan sites can share:
- Inventory information
- Production schedules
- Operational data
- Quality information
- Capacity planning data
This connected operating model allows resources and production capacity to be coordinated more efficiently across sites, strengthening resilience and helping maintain reliable global supply.
What Can Other Pharmaceutical Manufacturers Learn from the Project?
One of the strongest themes throughout the podcast episode was that successful innovation begins with operational needs rather than technology adoption alone.
According to Wei, manufacturers should focus first on solving critical business and production challenges, including:
- Capacity expansion
- Sterility assurance
- Process consistency
- Supply reliability
- Quality risk reduction
Technology becomes valuable when it directly addresses those objectives.
The Pingshan project demonstrates how automation, digitalization, AI, and human expertise can work together as part of a unified manufacturing strategy rather than as standalone initiatives.
How Do These Innovations Benefit Patients?
Ultimately, the facility's technology investments are intended to deliver patient benefits.
For patients, the most significant outcomes include:
- More consistent product quality
- Stronger sterility assurance
- Enhanced defect detection
- Improved supply reliability
- More dependable access to medicines
By reducing process variability and strengthening manufacturing controls, the facility helps ensure that safe, high-quality products reach patients when needed.
Looking Ahead
Hepalink's Shenzhen Pingshan New Pre-Filled Syringe Manufacturing Facility demonstrates how pharmaceutical manufacturers can combine facility design, automation, AI, and digital technologies to solve complex manufacturing challenges.
Rather than pursuing technology for its own sake, the project focused on practical outcomes: increasing capacity, strengthening sterility assurance, improving quality oversight, and building a more resilient supply network.
Those achievements helped earn the facility the 2026 ISPE Facility of the Year Awards Innovation – Novel Technology Category Award and provide a valuable example for manufacturers evaluating their own digital transformation strategies.
Listen to the Episode
Hear CaiXue Wei discuss the technologies, design decisions, and lessons learned behind Hepalink's FOYA-winning Pingshan facility and discover how AI, 5G, automation, and digital collaboration are helping shape the future of pharmaceutical manufacturing.
来源:ISPE iSpeak 专家博客 · ispe.org